| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 13, 2026 |
| Accession Number: | 0001193125-26-044611 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $15.00 → $12.00 | Neutral → Sell | Goldman |
| 2/1/2024 | $20.00 | Neutral | Goldman |
| 9/27/2022 | $22.00 | Mkt Outperform | JMP Securities |
| 1/6/2022 | $38.00 | Buy | Goldman |
| 12/29/2021 | $23.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/31/2021 | $20.00 → $23.00 | Buy | HC Wainwright & Co. |
| 8/6/2021 | $19.00 | Buy | Goldman Sachs |
| 8/5/2021 | $16.00 → $20.00 | Buy | HC Wainwright & Co. |
EFFECT - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec
Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi's presence in adult immunization by bringing together Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach.
EMERYVILLE, Calif., Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m. ET. The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. About DynavaxDynavax is a
Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously
Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00
JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec
Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit
ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc
EMERYVILLE, Calif., Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://in
Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant programConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)